Scientists at the University of Oxford demonstrate an approach to interpreting how materials interact with polarized light, ...
Non-terrestrial networks, combined with early 6G research, demand test equipment capable of handling extreme parameters and ...
TAMPA, Fla. and LONDON, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads, ...
Phase 1a/1b study in 97 patients demonstrates mitochondrial metabolic reprogramming induced by BPM31510-IV and supports advancement in multiple ...
Modern Engineering Marvels on MSN
Bright and dark photon states redefine light’s interference mystery
Perhaps one of the most famous experiments in physics has been giving us the wrong message all these years. For nearly two ...
Xenon Pharmaceuticals (XENE) is undervalued given azetukalner's late-stage potential to transform epilepsy and mood disorder ...
MedPage Today on MSN
Novel Pills Promising in Relapsed/Refractory Multiple Myeloma
Iberdomide and mezigdomide are currently being evaluated for the treatment of patients with multiple myeloma in a number of ...
Elliptical retarder model improves polarization analysis for material design and biomedical imaging. The work, reported in Advanced Photonics Nexus, focuses on improving how researchers analyze a key ...
In this article, we examine ongoing challenges shaping target-based drug discovery and highlight how new technologies and ...
Explore how the future of obesity drugs starts in preclinical discovery, addressing global challenges and advancing treatment ...
Scientists at the University of Oxford demonstrate an approach to interpreting how materials interact with polarized light, which could help advance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback